News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
296,724 Results
Type
Article (15753)
Company Profile (262)
Press Release (280700)
Multimedia
Podcasts (127)
Webinars (13)
Section
Business (90826)
Career Advice (170)
Deals (13526)
Drug Delivery (69)
Drug Development (51102)
Employer Resources (32)
FDA (6011)
Job Trends (5224)
News (145934)
Policy (10090)
Tag
2025 Best Places to Work (13)
2026 Best Places to Work (19)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Standard (3)
40 Under 40 (4)
Academia (978)
Accelerated approval (39)
ADA (34)
Adcomms (16)
Allergies (128)
Alliances (21770)
ALS (204)
Alzheimer's disease (1263)
Antibody-drug conjugate (ADC) (582)
Approvals (6441)
Artificial intelligence (491)
ASCO (224)
Autoimmune disease (410)
Automation (20)
Bankruptcy (112)
Belgium (30)
Best Places to Work (4559)
BIO (56)
Biologics (71)
BIOSECURE Act (6)
Biosimilars (161)
BioSpace Insights (81)
Biotechnology (179)
Bispecific (54)
Bladder cancer (143)
Brain cancer (73)
Breast cancer (510)
Cancer (5048)
Cardiovascular disease (375)
Career advice (174)
Career pathing (15)
CAR-T (347)
CDC (11)
CDMO (127)
Celiac Disease (6)
Cell therapy (889)
Cervical cancer (31)
Clinical research (46642)
Collaboration (1779)
Commercialization (44)
Company closure (4)
Compensation (988)
Complete response letters (73)
COVID-19 (1156)
CRISPR (131)
CRO (4)
C-suite (1057)
Cystic fibrosis (132)
Data (7642)
Denatured (27)
Depression (134)
Dermatology (131)
Diabetes (404)
Diagnostics (1562)
Digital health (21)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (360)
Drug pricing (55)
Drug shortages (4)
Duchenne muscular dystrophy (344)
Earnings (33924)
Editorial (37)
Employer branding (4)
Employer resources (30)
ESMO (311)
Events (55586)
Executive appointments (804)
Eye disease (16)
FDA (8826)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (36)
Funding (1495)
Gene editing (264)
Generative AI (50)
Gene therapy (725)
GLP-1 (638)
Government (1217)
Grass and pollen (3)
Guidances (182)
Healthcare (6833)
Hematology (144)
HIV (40)
Huntington's disease (75)
Idiopathic pulmonary fibrosis (10)
IgA nephropathy (125)
Immunology and inflammation (291)
Immuno-oncology (123)
Indications (191)
Infectious disease (1338)
Inflammatory bowel disease (216)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (262)
Interviews (21)
IPO (7422)
IRA (13)
Job creations (871)
Job search strategy (139)
JPM (41)
Kidney cancer (13)
Kidney disease (126)
Labor market (46)
Layoffs (280)
Leadership (22)
Legal (1406)
Licensing (99)
Liver cancer (54)
Longevity (39)
Lung cancer (701)
Lung diease (21)
Lymphoma (369)
Machine learning (37)
Management (8)
Manufacturing (713)
Marketing (25)
MASH (189)
Medical affairs (4)
Medical device (2759)
Medtech (2814)
Melanoma (110)
Mergers & acquisitions (6990)
Metabolic disorders (1117)
Middle East (1)
mRNA (230)
Multiple sclerosis (162)
Multispecific (6)
NASH (14)
Netherlands (19)
Neurodegenerative disease (433)
Neuropsychiatric disorders (105)
Neuroscience (2778)
Neurotech (2)
NextGen: Class of 2026 (2040)
Non-profit (891)
Now hiring (50)
Obesity (496)
Opinion (161)
Ovarian cancer (232)
Pain (175)
Pancreatic cancer (312)
Parkinson's disease (366)
Partnered (19)
Patents (512)
Patient advocacy (7)
Patient recruitment (682)
Patient selection (93)
Peanut (55)
People (27975)
Peptides (33)
Pharmaceutical (31)
Pharmacy benefit managers (9)
Phase 1 (16516)
Phase 2 (21706)
Phase 3 (13730)
Pipeline (9241)
Policy (114)
Postmarket research (853)
Preclinical (6977)
Press Release (30)
Prostate cancer (247)
Psychedelics (89)
Radioligand (3)
Radiopharmaceuticals (342)
Rare diseases (1133)
Real estate (1461)
Recruiting (12)
Regenerative medicine (24)
Regulatory (11460)
Reports (33)
Research institute (1008)
Resumes & cover letters (20)
Rett syndrome (51)
RNA editing (38)
RSV (26)
Schizophrenia (175)
Series A (295)
Series B (198)
Series C (1)
Service/supplier (1)
Sickle cell disease (110)
Special edition (24)
Spinal muscular atrophy (131)
Sponsored (22)
Startups (2057)
State (1)
Stem cells (7)
Stomach cancer (7)
Substance use disorders (20)
Supply chain (49)
Switzerland (15)
Tariffs (20)
The Weekly (98)
Vaccines (472)
Venture capital (120)
Weight loss (263)
Wet AMD (6)
Women's health (63)
Women in leadership (1)
Worklife (4)
Date
Last 7 days (395)
Last 30 days (2061)
Last 365 days (18396)
2026 (16919)
2025 (18094)
2024 (20467)
2023 (22412)
2022 (26810)
2021 (27802)
2020 (23355)
2019 (16222)
2018 (11735)
2017 (13743)
2016 (11838)
2015 (14348)
2014 (10392)
2013 (7483)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (160)
Alabama (86)
Alaska (2)
Arizona (108)
Arkansas (6)
Asia (19316)
Australia (3328)
California (10483)
Canada (2597)
China (1383)
Colorado (397)
Connecticut (395)
Delaware (364)
Europe (41379)
Florida (1380)
Georgia (289)
Hawaii (3)
Idaho (18)
Illinois (656)
India (78)
Indiana (246)
Iowa (13)
Japan (408)
Kansas (93)
Kentucky (13)
Louisiana (18)
Maine (14)
Maryland (1072)
Massachusetts (8370)
Michigan (143)
Minnesota (362)
Mississippi (4)
Missouri (41)
Montana (17)
Nebraska (6)
Nevada (71)
New Hampshire (22)
New Jersey (2357)
New Mexico (14)
New York (2545)
North Carolina (1214)
North Dakota (9)
Northern California (5449)
Ohio (254)
Oklahoma (12)
Oregon (28)
Pennsylvania (1899)
Puerto Rico (12)
Rhode Island (31)
South America (217)
South Carolina (20)
Southern California (4257)
Tennessee (72)
Texas (1505)
United States (34544)
Utah (145)
Virginia (212)
Washington D.C. (37)
Washington State (850)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
296,724 Results for "feldan therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FELDAN THERAPEUTICS REPORTS PRELIMINARY PHASE 1 RESULTS FOR FLD-103 IN NODULAR BASAL CELL CARCINOMA, DEMONSTRATING A GENERALLY WELL-TOLERATED SAFETY PROFILE AND SIGNS OF CLINICAL ACTIVITY IN EXPLORATORY ASSESSMENTS
November 19, 2026
·
7 min read
Press Releases
FELDAN THERAPEUTICS ACCELERATES GROWTH WITH STRATEGIC INVESTMENT FROM LINEARIS VENTURES
February 18, 2025
·
2 min read
Feldan Therapeutics Secures $16.5m Series B to Bring Lead Asset to Clinical Development
Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment.
June 13, 2023
·
4 min read
Feldan Therapeutics Awarded Funding by Cystic Fibrosis Foundation
Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced it was awarded funding by the Cystic Fibrosis Foundation to pursue the development of the Feldan Shuttle technology as a pulmonary delivery agent for cystic fibrosis.
January 18, 2022
·
1 min read
Press Releases
FELDAN THERAPEUTICS COMPLETES A US$ 21 MILLION SERIES B FINANCING CO-LED BY GENESYS CAPITAL AND FONDS DE SOLIDARITÉ FTQ
September 4, 2024
·
4 min read
Funding
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
Marrow Therapeutics aims to address safety and accessibility obstacles in genetic medicines by delivering therapies straight to bone marrow cells.
November 17, 2026
·
2 min read
·
Gabrielle Masson
Press Releases
Feldan Therapeutics Announces the treatment of the first patient in the Phase 1/2a clinical trial of its candidate FLD-103, against basal cell carcinoma
October 31, 2024
·
3 min read
Press Releases
Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
November 17, 2026
·
10 min read
Press Releases
Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
November 16, 2026
·
3 min read
Press Releases
Anacalypsis Therapeutics Raises Pre-Seed Financing Led by Metavallon VC to Advance a First-in-Class Therapeutic Strategy for Parkinson’s Disease
Athens-based biotech will use the financing to advance AT001, its lead therapeutic program targeting the LRRK2–FADD interaction, through a key in vivo efficacy study.
September 21, 2026
·
1 min read
1 of 29,673
Next